I nsulin growth factor-1 (IGF-1) plays an essential role in normal growth and brain development. 1 Substantial data indicate that IGF-1 exerts potent neuroprotective effects against acute ischemic brain injury. Administration of IGF-1 protein protects the developing or adult brain from experimental ischemia [2] [3] [4] [5] and cultured neurons from diverse forms of injury. 6, 7 Low levels of IGF-1 are associated with poor outcome in elderly patients with stroke, suggesting that endogenous IGF-1 level impacts the evolution of cerebral infarction. 8 In addition to its neuropotective activities, IGF-1 is also a potent angiogenic factor required for cerebral angiogenesis during development and in adulthood. 9 IGF-1 has been reported to enhance endothelial function through antiinflammatory and antiapoptotic properties. 10 Although IGF-1 has been established to protect neural cells against acute ischemic injury, a role for IGF-1 in long-term neurological recovery after ischemic stroke has not been demonstrated. In this study, we investigated whether IGF-1 overexpression enhances neurovascular remodeling and improves long-term functional outcome in a mouse model of permanent focal cerebral ischemia. Recombinant adenoassociated viral vector (AAV) was used to deliver IGF-1 to the brain and to achieve efficient IGF-1 production over long periods of time.
Materials and Methods

Adeno-Associated Viral Vector Delivery
This study was approved by the University of California, San Francisco Committee of Animal Research and conformed to the National Institutes of Health Guidelines for use of animals in research. Viral transduction was performed as described. 11 Briefly, adult CD-1 mice weighing 30 to 35 g were placed in a stereotactic frame (Kopf, Tujunga, Calif) under anesthesia, and a burr hole was drilled 2.5 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture. A 10-L Hamilton syringe was slowly inserted into the left caudate nucleus (3.0 mm deep from the dura). Four microliters viral suspension (AAV-IGF-1 or AAV-green fluorescent protein [GFP] ) containing 2ϫ10 10 particles was injected into the left hemisphere (injection sites are depicted in Figure 1A ). Recombinant AAV serotype 2 (rAAV2) containing human IGF-1 or GFP was provided by Ceregene Inc (San Diego, Calif). AAV serotype 2 has been shown to only transfect postmitotic neurons. 12 Systemic coadministration of mannitol has been demonstrated to profoundly amplify rAAV2 transduction efficiency. 12 Thus, in our experiments, the mice were injected intraperitoneally with 3 mL of sterile 25% mannitol in 0.9% saline per 100 g body weight 15 minutes before intracerebral vector injection.
Animal Stroke Model
Three weeks after gene transfer, the mice were subjected to permanent focal ischemia by distal middle cerebral artery occlusion (MCAO). 13 The left middle cerebral artery was occluded by electric coagulation just proximal to the pyriform branch. Body temperature was maintained at 37Ϯ0.5°C by using a thermal blanket throughout the surgical procedure. Surface cerebral blood flow was monitored during MCAO using a laser Doppler flowmeter (Vasamedics Inc). Mice with surface cerebral blood flow that was more than 15% of the baseline were excluded from the experiment.
5-bromo-2-deoxyuridine-5-monophosphate-Labeling
5-bromo-2-deoxyuridine-5-monophosphate (BrdU), a thymidine analog incorporated into the DNA of dividing cells, was used to track proliferating cells. Before euthanization, mice were intraperitoneally injected twice daily with BrdU (50 mg/kg; Sigma) for 7 consecutive days.
Western Blotting
The protein concentration was determined using the BCA protein assay kits (Pierce, Ill). Equal amounts of proteins were loaded on 10% acrylamide gel for electrophoresis and were electroblotted onto a polyvinyl difluoride membrane. The membranes were then probed with mouse anti-IGF-1 antibody, 1:500 (Upstate, the antibody reacts with IGF-1 from human and mouse origin) followed by incubation with horseradish-peroxidase-conjugated sheep antimouse IgG (BioRad Laboratories). Protein expression was detected with an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech Inc). Beta-actin was used as a loading control. 
Immunohistochemistry
Immunohistochemical staining was performed as described. 11 Briefly, sections were incubated with primary antibodies at the following concentrations: mouse anti-IGF-1, 1:100 (Upstate), rat anti-CD31, 1:200 (BD Bioscience), mouse anti-BrdU, 1:1000 (Sigma), and rabbit antidoublecortin (DCX), 1:200 (Cell Signaling). After incubating at 4°C overnight and washing, the sections were incubated with biotinylated secondary antibody (Vector Laboratories) at 1:5000 dilution. The sections were treated with the ABC streptavidin detection system. For dual fluorescent staining, after incubating with primary antibodies, sections were incubated with Alexa Fluor 594-conjugated or Alexa Fluor 488-conjugated IgG (Molecular Probes) at 1:500 dilution. Negative controls were performed by omitting the primary antibodies during the immunostaining.
Behavioral Tests
A set of behavioral tests was performed 1 day before MCAO (as baseline values) and 21 days after MCAO by an investigator masked to the experimental groups.
Corner test was used to detect sensorimotor and postural asymmetries. 14 Mice were placed between the 2 angled boards facing the corner. When entering deep into the corner, the vibrissae on both sides were stimulated simultaneously. The mouse would then rear forward and upward, and then turn back to face the open end. The nonischemic animals would turn back from either left or right randomly. The ischemic animals would preferentially turn toward the ipsilateral side. The number of turns taken to each side was recorded from 10 trials for each test. Turning movements that were not part of a rearing movement were not scored. Data are presented as normalized turn ratio out of 10 trials.
Body Asymmetry Test
To measure motor asymmetry, mice were examined by elevated body swing test as described. 15 Mice were examined for head swings while being suspended by their tails. The direction of the swing, either right or left, was recorded when the mouse turned its head sideways by approximately at a 10 o angle to the body's midline. After each swing, the mouse was allowed to move freely in a Plexiglas box for at least 30 seconds before taking the next test; the trials were repeated 20 times for each animal. The frequency of head swings toward the contralateral side was counted and normalized as follows:
͑number of lateral swings in 20 testsϪ10)/10ϫ100%.
Beam Test
Beam walking across a bridge was used to assess motor coordination and balance after stroke injury. 16 Mice were trained for 5 days before MCAO to traverse a narrow round beam (5 mm diameter and 900 mm in length) to reach an enclosed escape platform. They were placed on one end of the beam and the latency to traverse the central 80% of the beam toward the enclosed escape platform at the other end was recorded. Data are expressed as mean latency to cross the beam of 3 trials.
Evaluation of Cerebral Infarction
Twenty-one days after MCAO, mice were euthanized so their brains could be examined histologically for infarct volume and secondary end points (see subsequently). Serial coronal sections (200 m apart) were stained with cresyl violet for assessing infarct volume. Sections were digitized, and the area of infarct and noninfarct tissues was outlined using National Institutes of Health Image J. Infarct volume was calculated by multiplying the appropriate area by the section interval thickness. Infarct volume was indirectly determined by subtracting the volume of intact tissue in the ipsilateral hemisphere from that in the contralateral hemisphere. 17 
Vascular Density Assessment
Microvessel counting was performed as described. 11 Briefly, 2 brain coronal sections from the CD31-stained brain sections, 1 mm anterior and 1 mm posterior from the needle track, were chosen. Three areas of microvessels, immediate to the left, right, and bottom of the needle track, were photographed using a 10ϫ objective. Three random areas in the perifocal region were also photographed. Microvessel counting and cell counting (BrdU and CD31 duallabeled cells) were performed on these photographs. Vessels with a diameter between 3 and 8 mol/L were counted. The number of microvessels was calculated as the mean of the vascular counts obtained from 3 pictures; the number of cells was calculated in the same manner. The counting was conducted in a blinded fashion.
Cerebral Blood Flow Measurement
For surface cerebral blood flow measurement, a laser Doppler flowmetry monitor equipped with a small-caliber probe 0.7 mm in diameter was used. The laser Doppler probe was in contact with the surface of the mice's skull bone during measurement. Blood flow was recorded in the ischemic penumbra area, which is 1.0 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture. Baseline blood flow was recorded 5 minutes before MCAO. Changes in cerebral blood flow were measured immediately, 1 week, and 3 weeks after MCAO. Blood flow values are calculated and expressed as percentages of baseline values. 11
Cell Counting
Quantification of DCXϩ and BrdUϩ cells was performed as described. 18 DCXϩ and BrdUϩ cells in the ipsilateral subventricular zone (the area that lines the lateral walls of the lateral ventricle and is a predominant source of neuronal progenitors) were digitized under a 20ϫ objective with a spot camera (Leica) equipped with National Institutes of Health Image J software. To clearly differentiate positively stained cells from the background, the digitalized images were contrast-enhanced and a threshold parameter was established to assess the proportion of immunoreactive region within a fixed field of view. The thresholds were selected with a "set color threshold" feature in the Image J software, which permits the user to select pixel regions that were considered positive. After establishment, the same parameter was applied to all images acquired under the same magnification and light intensities on slides that were processed identically. The signals were counted using 4 sections from each mouse and the numbers were averaged. The data are presented as numbers of positive cells per microscopic field.
Statistical Analysis
Data are presented as meanϮSD. Parametric data from the AAV-IGF-1, AAV-GFP, and saline-treated groups were compared using a one-way analysis of variance followed by Fisher protected least significant difference test, as appropriate. A probability value Ͻ0.05 is considered statistically significant.
Results
Adeno-Associated Viral Vector-Mediated Gene Transduction and Expression
To determine whether intraparenchymal AAV injection leads to successful gene transduction and expression, we first examined the extent of GFP expression after AAV-GFP infection. As shown in Figures 1C and 1D , a robust GFP signal was observed adjacent and distal to the injection tract as well as in the periinfarct region 3 weeks after MCAO (6 weeks postinjection). Previous experiments showed that GFP signal could be detected as early as 2 weeks after AAV transduction (data not shown). In contrast, GFP signal was absent in the contralateral noninjected hemisphere ( Figure  1B) . AAV-IGF-1 administration resulted in increased IGF-1 protein levels compared with AAV-GFP-administered mice as assessed by Western blot analysis ( Figure 1E-F, PϽ0 .01) 3 weeks after MCAO. IGF-1 expression was also present in GFP-injected mice, which might be reflective of endogenous IGF-1 protein expressed after the ischemia. Furthermore, immunohistochemical staining revealed intense IGF-1 immunoreactivity in IGF-1-transduced mice, but not in GFPinjected mice ( Figure 1G ). These data indicate that AAV efficiently delivered IGF-1 to a large area of the ischemic penumbra, not limited to the injection sites, with a prolonged expression period.
Insulin Growth Factor-1 Gene Transduction Confers Improved Neurological Behavior and Reduced Hemispheric Atrophy After Cerebral Ischemia
After demonstrating efficient gene transfer, we investigated whether IGF-1 overexpression would improve neurological functions after ischemic stroke. Three weeks after AAVmediated gene transfer, mice were subjected to ischemic injury by permanent MCAO. Compared with the stroke mice with AAV-GFP or saline treatment, those with AAV-IGF-1 transduction showed dramatically improved motor performance as assessed by corner test, body asymmetry trials, and beam test (Figure 2, PϽ0.05) . Furthermore, AAV-IGF-1 treatment significantly reduced the infarct volume compared with AAV-GFP or saline treatment (Figure 3 ; AAV-IGF-1 versus AAV-GFP versus saline: 16 
Insulin Growth Factor-1 Overexpression Increases Vascular Density and Cerebral Blood Flow
Immunohistochemical analysis using an antibody against endothelial cell marker CD31 showed increased vascular density in the penumbra of AAV-IGF-1-treated hemispheres (112Ϯ12, number of microvessels/field) compared with AAV-GFP (54Ϯ6) or saline-injected hemispheres (51Ϯ5; Figure 4A (Table; percentages of baseline values, PϽ0.05). There was no difference in blood flow among the 3 groups assessed immediately or 1 week after MCAO.
Transfer of Insulin Growth Factor-1 Gene Enhances Neurogenesis
To examine whether IGF-1 overexpression enhances neurogenesis, we performed immunohistochemcal analysis using antibodies against the cell proliferation marker BrdU and DCX, a specific marker for immature neurons. As shown in Figures 5A and 5B, IGF-1 gene transfer resulted in pronounced elevation of BrdUϩ cells in the subventricular zone 
Discussion
The present study is the first to demonstrate that IGF-1 gene transfer effectively improved the functional outcome, which was coupled with enhanced angiogenesis and neurogenesis, assessed in the chronic stage of cerebral infarction. Endogenous IGF-1 level is upregulated after cerebral ischemia, suggesting that IGF-1 may mediate endogenous protection or repair in the ischemic lesion. 2, 19 Endogenously elevated IGF-1 may not be sufficient to counteract the injury, and therapeutic administration is needed to augment the trophic support to sustain long-term stroke protection. Several studies have reported that exogenous IGF-1 protein delivery effectively reduces the extent of neuronal damage and neurological deficits in the acute phase of ischemic injury assessed from 24 hours to 7 days. 20, 21 However, the effect of IGF-1 treatment on the long-term neurological functions after ischemic stroke has not been reported. In this study, we used AAV to achieve sustained IGF-1 overexpression in the ischemic hemisphere. The advantage of gene transfer is that a single injection of vector can lead to efficient production of proteins over a widely distributed target area for an extended period of time. Thus, gene transfer offers significant advantages over approaches that rely on administration of protein from a single point source (whether through multiple injections over time or chronic infusions involving indwelling 
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hardware); these advantages include more widespread coverage and simplicity of long-term protein exposures. In addition, compared with other viral vectors such as adenoviral vector, AAV vector has several advantages such as the ability to mediate long-term transgene expression and low immunogenicity. 22 IGF-1 overexpression was sustained for at least 6 weeks after AAV transfer as shown by Western blot and immunohistochemical analysis. After synthesis and secretion, IGF-1 could diffuse readily through tissues, a property that permits it to signal over long distances. 23 We demonstrated here that IGF-1 overexpression effectively enhanced motor function, assessed at 3 weeks after MCAO, compared with GFP or saline treatment. The improved behavior performance correlated with a reduction in stroke-induced brain atrophy. Although IGF-1 is an angiogenic factor and reported to mediate vascular growth in developing and adult brain, 9 its role in vascular remolding after cerebral ischemia has not been studied. Our data show that IGF-1 treatment produced increased microvessels in the periinfarct region along with increased local blood flow. Improved microcirculation is likely to enhance neural cell survival, support neurogenesis, and help the removal of necrotic brain tissue to facilitate the repair process ultimately leading to long-term functional recovery. Consistent with this notion, several studies have shown that restoration of perfusion by collateral growth or new capillaries facilitates functional improvement after stroke. 24 -26 Neurogenesis persists in the adult brain and could be enhanced by ischemic injury and various growth factors. 27 Inhibiting endogenous IGF-1 activity prevents focal ischemia-induced neurogenesis. 19 We demonstrated here that IGF-1 gene transfer increased the number of newly formed neurons in the SVZ area of infarcted hemispheres compared with ischemic injured hemispheres with GFP gene transfer. Our finding is consistent with the report that IGF-1 protein infusion through osmotic minipump increases stroke-induced progenitor cell proliferation in hypertensive rats. 28 Together with these studies, our data indicate that neurogenesis can be amplified by administration of exogenous growth factors such as IGF-1 to promote the healing of the ischemic brain. Angiogenesis and neurogenesis are linked in a temporal and spatial manner. 29, 30 Their interdependence emerges in development with concurrent growth and remodeling. Vascular cells secrete trophic factors such as SDF-1 or Ang1 to promote neural progenitor cells to proliferate and migrate to regions of damage. 30 Taken together, enhanced neovascularization and neurogenesis could be the essential mechanisms by which IGF-1 enhances functional recovery after MCAO.
In this study, AAV-IGF-1 was injected before MCAO to allow maximal expression of IGF-1. This experimental paradigm minimizes the usefulness of clinical applications. However, pretreatment is also of interest primarily as proof of concept that IGF-1 transduction could promote long-lasting functional recovery after cerebral infarction. In addition to enhanced angiogenesis and neurogenesis, the improved neurological function and reduced brain atrophy could also be contributed by the neuroprotective effects of IGF-1 in the acute phase of stroke. Because the acute neuroprotective action of IGF-1 has been well demonstrated, in the present study, we focused our effort on studying the neural regenerative effect of IGF-1. Targeting the neurovascular unit with neurotrophic and angiogenic IGF-1 may represent a novel regenerative paradigm for patients with stroke. Future experiments are needed to assess the restorative effects of IGF-1 by postischemic gene transfer.
